Clinical trials: Androgenic Alopecia, active
Androgenetic Alopecia
A Split-Scalp Study Evaluating the Efficacy and Safety of Fractional Laser Therapy With and Without Exosomes in the Treatment of Androgenetic Alopecia
This trial aims to evaluate the efficacy, safety, and tolerability of fractional laser combined with topical exosome for hair regrowth in patients with androgenetic alopecia. This study is expected to recruit 30 participants.
- Trial name
- NCT07248410
- Testing
- fraction laser
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Chang Gung Memorial Hospital
Androgenetic Alopecia (AGA)
Thulium Laser and Growth Factors for Androgenetic Alopecia
Androgenetic alopecia (AGA) is a common cause of hair loss worldwide. It mainly affects the frontal and parietal regions of the scalp in up to 70 % of men and 40 % of women and has a significant negative psychological and…
- Trial name
- NCT07079657
- Testing
- Thulium laser + growth factor serum + LED, Thulium laser + growth factor serum, Thulium laser
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Androgenic Alopecia
Umbilical Cord-derived Mesenchymal Stem Cell Exosomes on Hair Growth in Patients With Androgenetic Alopecia
A total of 50 patients with androgenetic alopecia were selected for the study. Patients who met the inclusion/exclusion criteria were randomly assigned to groups A and B in a 1:1 ratio to receive treatment, with the enrollment…
- Trial name
- NCT06697080
- Testing
- Human umbilical cord mesenchymal stem cells
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Androgenic Alopecia, Healthy Adult Male
Efficacy and Safety of Two Hair Supplements in Men With Androgenic Alopecia
The goal of this clinical trial is to evaluate the efficacy and safety of two different formulations of a food supplement on hair health in healthy Caucasian male subjects aged 35 to 65 years with mild to moderate androgenetic…
- Trial name
- NCT07806474
- Testing
- formulation of green tea leaf extract, bamboo shoot extract and selenium-enriched yeast, formulation of grape seed extract, bamboo shoot extract and selenium-enriched yeast
- Where
- 6 sites in Italy
- Volunteers
- 99 people
- Sponsor
- Activ'inside
Androgenetic Alopecia, Androgenic Alopecia
JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil
Androgenetic alopecia is a common form of progressive hair loss. This prospective single-arm pre-post interventional study aims to assess tissue Janus Kinase 2 (JAK2) expression in patients with androgenetic alopecia by comparing…
- Trial name
- NCT07563036
- Testing
- Topical Minoxidil 5% Solution, Scalp Punch Biopsy, Tissue JAK2 Protein Measurement by ELISA
- Where
- Egypt
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Kasr El Aini Hospital
Androgenetic Alopecia
Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia
This is a randomized, open-label phase 1/2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia.
- Trial name
- NCT07490327
- Testing
- AD-303A, AD-3031
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Moogene Medi Co., Ltd
Androgenetic Alopecia
Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients
This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr.
- Trial name
- NCT07429253
- Testing
- Secretome, Platelet-Rich Plasma (PRP) Injections
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Alopecia, Androgenetic
Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
The purpose of this study is to evaluate the efficacy and safety of APSMNF in the treatment of male androgenetic alopecia.
- Trial name
- MONA (NCT07516561)
- Testing
- APSMNF 1, APSMNF 2, Eniagor®
- Where
- Brazil
- Volunteers
- 336 people
- Sponsor
- Apsen Farmaceutica S.A.
Androgenetic Alopecia
Efficacy of Botulinum Toxin A Versus Nanofat in the Treatment of Androgenetic Alopecia: A Comparative Clinical Trial
The goal of this clinical trial is to learn whether botulinum toxin A (BTA) or autologous nanofat injection is more effective for treating male androgenetic alopecia. It will also assess the safety of both treatments.
- Trial name
- AGA (NCT07863856)
- Testing
- Botulinum Toxin Type A, Autologous Nanofat Injection
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Sherief Ayman Hussein Shaamash
Androgenetic Alopecia, AGA
Safety and Efficacy of VDPHL01 in Males and Females With AGA
This study will evaluate the safety and efficacy of VDPHL01 in male and female subjects with Androgenetic Alopecia (AGA). AGA (or pattern of hair loss) is a genetic disorder caused by an excessive (too much) hair follicle…
- Conditions
- Androgenetic Alopecia, AGA, Male Pattern Baldness
- Trial name
- NCT06527365
- Testing
- VDPHL01
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Veradermics, Inc.
Androgenetic Alopecia, Female Pattern Baldness
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
This phase III clinical trial is evaluating whether oral minoxidil 1 mg is an effective and safe treatment for women with androgenetic alopecia (female pattern hair loss).
- Trial name
- NCT05888922
- Testing
- Minoxidil Tablets, Minoxidil Topical, Vehicle solution
- Where
- 27 sites in Germany, Italy and 2 more
- Volunteers
- 520 people
- Sponsor
- Industrial Farmacéutica Cantabria, S.A.
Androgenetic Alopecia
Comparing Standard Platelet-Rich Plasma and Light-Enhanced Platelet-Rich Plasma for Treating Hair Loss in Androgenetic Alopecia: A Randomized Controlled Trial
The goal of this clinical trial is to compare 3 different types of PRP in androgenetic alopecia patients. The main questions it aims to answer: Does Redlight enhanced, Blue light enhanced, or traditional PRP result in higher hair…
- Trial name
- NCT07739147
- Testing
- Platelet-Rich Plasma (PRP) Injections, Red-light photobiomodulation with cooling, Blue-light photobiomodulation
- Volunteers
- 30 people
- Sponsor
- Kimberly Meathrel
Androgenetic Alopecia (AGA), Androgenetic Alopecia
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that…
- Conditions
- Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia
- Trial name
- NCT07146022
- Testing
- VDPHL01 QD, VDPHL01 BID
- Where
- 71 sites in United States
- Volunteers
- 552 people
- Sponsor
- Veradermics, Inc.
Androgenetic Alopecia
Study to Evaluate Xtressé Gummy Supplement in Women With Thinning Hair
The goal of this study is to determine how much Xtresse' gummy taken daily changes hair density in women with self-perceived thinning hair compared with placebo.
- Trial name
- NCT07919782
- Testing
- Xtressé Hair Growth Gummies
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Androgenetic Alopecia
Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia
The purpose of this study is to evaluate the efficacy of Finlândia hair lotion association in the treatment of androgenetic alopecia.
- Trial name
- NCT04594018
- Testing
- Minoxidil + finasteride
- Where
- Brazil
- Volunteers
- 190 people
- Sponsor
- EMS
Androgenetic Alopecia
Six-Month Single-Blind, Placebo-Controlled Study of a Dietary Supplement Supplement on Hair Growth in 45 Volunteers
This clinical study is designed to evaluate the efficacy and safety of a dietary supplement CL-P24113a for the management of androgenetic alopecia (AGA) in male subjects aged 18 to 45 years who suffer from alopecia with low hair…
- Trial name
- NCT06841458
- Testing
- Oral Supplement
- Where
- 2 sites in Spain
- Volunteers
- 45 people
- Sponsor
- Industrial Farmacéutica Cantabria, S.A.
Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia
This is a first-in-human study of ABS-201, a new investigational medicine, in healthy adult men and women. Its main purpose is to find out whether ABS-201 is safe and well tolerated, as well as to understand how the body…
- Trial name
- NCT07317544
- Testing
- SAD IV Dose 1 - 150mg ABS201 IV Single Dose, ABS-201 SC Multiple Doses
- Where
- 5 sites in Australia
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Absci Pty Ltd.
Androgenetic Alopecia
A Study on the Efficacy and Safety of Microneedling for Male Androgenetic Alopecia
Androgenetic alopecia (AGA) is the most prevalent hair-loss disorder in clinical practice. With a high incidence rate, it not only severely impairs patients' appearance and quality of life, but may also trigger varying degrees of…
- Trial name
- NCT07758400
- Testing
- Minoxidil 5 %, Microneedling
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Cheng Zhou
Androgenetic Alopecia, Androgenetic Alopecia (AGA)
The Effect of Nanofat Injection on Androgenetic Alopecia
Androgenetic alopecia is a condition that bothers a lot of people. The disadvantage of the FDA approved topical minoxidil is that the patient needs to be compliant every day for extended periods of time.
- Trial name
- NCT07518342
- Testing
- Minoxidil 5 %, PRP injection, Nanofat injection
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Androgenetic Alopecia (AGA)
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
This study is designed to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
- Trial name
- NCT07327359
- Testing
- OLX72021
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Olix Pharmaceuticals, Inc.